Saturday, October 10, 2015

BioClinica, Novo Nordisk report growth

Area pharma companies BioClinica and Novo Nordisk both said this week they are growing in what they do best.

BioClinica, Novo Nordisk report growth


Area pharmaceutical companies BioClinica and Novo Nordisk both said this week they are growing in what they do best.

BioClinica, which is based in Newtown, Bucks County, is a contract research organization (CRO) which means it administers clinical trials all over the globe for drug companies.

BioClinica said revenues increased from $16.9 million to $19.1 million (an increase of 12.8 percent) as compared with the same period in 2011. Using GAAP formula, BioClinica said its profit rose from $924,000 to $1 million for the same period.

The link to the BioClinica press release and report is here.

Novo Nordisk is based in Denmark, but has a big operation in Princeton and is perhaps an outsized player in the huge space of diabetes care.

Reuters reported that Novo predicts full-year sales growth of 9 to 12 percent, versus the previous forecast range of 8 to 11 percent, using local currencies. Novo also predicted operating profits of 15 percent for the year.

The link to the Reuters story is here.



Inquirer Staff Writer
We encourage respectful comments but reserve the right to delete anything that doesn't contribute to an engaging dialogue.
Help us moderate this thread by flagging comments that violate our guidelines.

Comment policy: comments are intended to be civil, friendly conversations. Please treat other participants with respect and in a way that you would want to be treated. You are responsible for what you say. And please, stay on topic. If you see an objectionable post, please report it to us using the "Report Abuse" option.

Please note that comments are monitored by staff. We reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable. Personal attacks, especially on other participants, are not permitted. We reserve the right to permanently block any user who violates these terms and conditions.

Additionally comments that are long, have multiple paragraph breaks, include code, or include hyperlinks may not be posted.

Read 0 comments
comments powered by Disqus
About this blog
David Sell blogs about the region's pharmaceutical industry. Follow him on Facebook.

Portions of this blog may also be found in the Inquirer's Sunday Health Section.

Reach David at or 215-854-4506.

David Sell Inquirer Staff Writer
Also on
letter icon Newsletter